{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T05:27:19Z","timestamp":1737696439730,"version":"3.33.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T00:00:00Z","timestamp":1733011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T00:00:00Z","timestamp":1711238400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","canadianjournalofophthalmology.ca","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2024,12]]},"DOI":"10.1016\/j.jcjo.2024.03.007","type":"journal-article","created":{"date-parts":[[2024,4,4]],"date-time":"2024-04-04T07:33:32Z","timestamp":1712216012000},"page":"e775-e783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma"],"prefix":"10.1016","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4506-4388","authenticated-orcid":false,"given":"Jeremy P.M.","family":"Flanagan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0040-9880","authenticated-orcid":false,"given":"Lotte S.","family":"Fog","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melvin A.","family":"Astrahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2233-1532","authenticated-orcid":false,"given":"Lachie J.","family":"Talbot","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0539-3515","authenticated-orcid":false,"given":"Daniel","family":"McKay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7215-8729","authenticated-orcid":false,"given":"Claire","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5790-5850","authenticated-orcid":false,"given":"John D.","family":"McKenzie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3916-4582","authenticated-orcid":false,"given":"Roderick","family":"O'Day","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2024.03.007_bib0001","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1097\/IAE.0b013e31824d09a8","article-title":"Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases","volume":"32","author":"Shields","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0002","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/archopht.119.7.969","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18","volume":"119","author":"Diener-West","year":"2001","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0003","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1001\/archopht.124.12.1684","article-title":"The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28","volume":"124","year":"2006","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0004","doi-asserted-by":"crossref","first-page":"S464","DOI":"10.1016\/S0167-8140(22)03984-6","article-title":"SP-0526 GEC-ESTRO survey on global Ru-106 eye plaque brachytherapy practice","volume":"170","author":"Fog","year":"2022","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0005","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.brachy.2015.04.010","article-title":"Outcomes of medium choroidal melanomas treated with ruthenium brachytherapy guided by three-dimensional pretreatment modeling","volume":"14","author":"Browne","year":"2015","journal-title":"Brachytherapy"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0006","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.brachy.2014.04.002","article-title":"(106)Ru plaque brachytherapy for uveal melanoma: factors associated with local tumor recurrence","volume":"13","author":"Barker","year":"2014","journal-title":"Brachytherapy"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0007","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1097\/IAE.0000000000000202","article-title":"Management of choroidal melanomas less than 10 mm in largest basal diameter with a 10-mm ruthenium plaque","volume":"34","author":"Salkola","year":"2014","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754108","article-title":"Long-term outcomes in uveal melanoma after ruthenium-106 brachytherapy","volume":"11","author":"Cennamo","year":"2022","journal-title":"Front Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0009","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1186\/s12886-022-02521-9","article-title":"Ruthenium-106 plaque radiotherapy for uveal melanoma: analysis of tumor dimension and location on anatomical and functional results","volume":"22","author":"Mirshahi","year":"2022","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0010","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.radonc.2010.03.023","article-title":"Long-term outcomes of eye-conserving treatment with Ruthenium(106) brachytherapy for choroidal melanoma","volume":"95","author":"Verschueren","year":"2010","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0011","doi-asserted-by":"crossref","first-page":"66","DOI":"10.5114\/jcb.2016.57818","article-title":"Ruthenium-106 brachytherapy for thick uveal melanoma: reappraisal of apex and base dose radiation and dose rate","volume":"8","author":"Naseripour","year":"2016","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0012","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1007\/s00417-012-1962-3","article-title":"Eccentric ruthenium plaque radiotherapy of posterior choroidal melanoma","volume":"250","author":"Russo","year":"2012","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0013","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13014-020-01621-4","article-title":"106Ruthenium eye plaque brachytherapy in the management of medium sized uveal melanoma","volume":"15","author":"Jiang","year":"2020","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0014","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.ijrobp.2005.02.059","article-title":"Visual acuity after Ruthenium(106) brachytherapy of choroidal melanomas","volume":"63","author":"Damato","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0015","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1136\/bjophthalmol-2018-313419","article-title":"Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with a thickness of \u22655.5 mm","volume":"104","author":"Fil\u00ec","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0016","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1259\/bjr\/76813976","article-title":"Dosimetric comparison of 106Ru and 125I plaques for treatment of shallow (<or=5 mm) choroidal melanoma lesions","volume":"81","author":"Wilkinson","year":"2008","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0017","doi-asserted-by":"crossref","first-page":"e169","DOI":"10.1016\/j.prro.2014.09.005","article-title":"A choice of radionuclide: comparative outcomes and toxicity of ruthenium-106 and iodine-125 in the definitive treatment of uveal melanoma","volume":"5","author":"Takiar","year":"2015","journal-title":"Pract Radiat Oncol"},{"year":"1995","series-title":"COMS Manual of Procedures","key":"10.1016\/j.jcjo.2024.03.007_bib0018"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0019","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brachy.2013.11.008","article-title":"The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma","volume":"13","year":"2014","journal-title":"Brachytherapy"},{"year":"2009","first-page":"375","series-title":"Basic Clinical Radiobiology","key":"10.1016\/j.jcjo.2024.03.007_bib0020"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0021","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0360-3016(94)00354-N","article-title":"Dose-response relationship for radiation therapy of subclinical disease","volume":"31","author":"Withers","year":"1995","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0022","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1111\/1754-9485.12008","article-title":"Defining a dose-response relationship for prostate external beam radiotherapy","volume":"57","author":"Trada","year":"2013","journal-title":"J Med Imaging Radiat Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0023","doi-asserted-by":"crossref","first-page":"851","DOI":"10.3109\/02841869509127196","article-title":"Volume and heterogeneity dependence of the dose-response relationship for head and neck tumours","volume":"34","author":"Agren Cronqvist","year":"1995","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0024","doi-asserted-by":"crossref","DOI":"10.1259\/bjr.20160666","article-title":"Fractionated stereotactic radiation therapy for brain metastases: a systematic review with tumour control probability modelling","volume":"90","author":"Baliga","year":"2017","journal-title":"Br J Radiol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0025","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1080\/0284186X.2020.1762925","article-title":"Tumour control probability after Ruthenium-106 brachytherapy for choroidal melanomas","volume":"59","author":"Espensen","year":"2020","journal-title":"Acta Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0026","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.canrad.2011.04.003","article-title":"State of the art on dose prescription, reporting and recording in Intensity-Modulated Radiation Therapy (ICRU report No. 83)","volume":"15","author":"Gr\u00e9goire","year":"2011","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0027","doi-asserted-by":"crossref","first-page":"e654","DOI":"10.1111\/aos.14663","article-title":"3D image-guided treatment planning for Ruthenium-106 brachytherapy of choroidal melanomas","volume":"99","author":"Espensen","year":"2021","journal-title":"Acta Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0028","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archophthalmol.2007.9","article-title":"Tilting of radioactive plaques after initial accurate placement for treatment of uveal melanoma","volume":"126","author":"Almony","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0029","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/j.ijrobp.2005.02.017","article-title":"Local tumor control after 106Ru brachytherapy of choroidal melanoma","volume":"63","author":"Damato","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0030","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/bjo.2009.176198","article-title":"Predicting local control of choroidal melanomas following \u00b9\u2070\u2076Ru plaque brachytherapy","volume":"95","author":"Papageorgiou","year":"2011","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0031","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1159\/000362560","article-title":"Monte Carlo simulation of the treatment of eye tumors with (106)Ru plaques: a study on maximum tumor height and eccentric placement","volume":"1","author":"Brualla","year":"2014","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0032","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1159\/000492599","article-title":"Monte Carlo simulation of the treatment of uveal melanoma using measured heterogeneous 106Ru plaques","volume":"5","author":"Zaragoza","year":"2019","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0033","doi-asserted-by":"crossref","first-page":"442","DOI":"10.5114\/jcb.2023.133614","article-title":"Quantifying the effect of eccentric ruthenium plaque placement on tumor volume dose","volume":"15","author":"Flanagan","year":"2023","journal-title":"J Contemp Brachytherapy"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0034","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1159\/000456717","article-title":"Monte Carlo Estimation of Absorbed Dose Distributions Obtained from Heterogeneous 106Ru Eye Plaques","volume":"3","author":"Zaragoza","year":"2017","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0035","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000479558","article-title":"Dose distributions and treatment margins in ocular brachytherapy with 106Ru eye plaques","volume":"4","author":"St\u00f6ckel","year":"2018","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0036","first-page":"6353","article-title":"Monte Carlo computation of dose-volume histograms in structures at risk of an eye irradiated with heterogeneous ruthenium-106 plaques","author":"Zaragoza","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0037","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.radonc.2017.01.010","article-title":"Treatment plan optimization and robustness of 106Ru eye plaque brachytherapy using a novel software tool","volume":"123","author":"Heilemann","year":"2017","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.jcjo.2024.03.007_bib0038","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/j.1755-3768.2010.01967.x","article-title":"Ruthenium plaque radiation therapy for iris and iridociliary melanomas","volume":"90","author":"Razzaq","year":"2012","journal-title":"Acta Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224000747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418224000747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T01:23:10Z","timestamp":1737681790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418224000747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12]]},"references-count":38,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["S0008418224000747"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.007","relation":{},"ISSN":["0008-4182"],"issn-type":[{"type":"print","value":"0008-4182"}],"subject":[],"published":{"date-parts":[[2024,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Apical dose versus volume dose of Ruthenium-106 brachytherapy for uveal melanoma","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2024.03.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of Canadian Ophthalmological Society.","name":"copyright","label":"Copyright"}]}}